Drug Discovery Opinion

Polo-like kinase 1 (Plk1) has received attention in recent years as a potential target for intervention in cancer. It is known to be important in regulation of cell cycle progression during M-phase and has been shown to be overexpressed in certain tumours. Now scientists at the NYU Cancer Institute and Howard Hughes Medical Institute have shown that Plk1 is involved in a new pathway associated with the cellular response to DNA damage. In the July 25th issue of Cell, the authors describe targeting of the phosphatase Cdc14B to APC/C, a protein that marks other proteins for destruction. The resultant activated APC/C then tags Plk1 for destruction. If Plk1 remains active, the cell continues to divide despite the DNA damage.

Tekmira Pharmaceuticals, a specialist in delivery of RNA interference molecules, has just announced plans to advance an siRNA product targeting Plk1 into Phase 1 clinical trials in the second half of 2009. Meanwhile, the search for small molecule inhibitors of Plk1 continues. Scientists at Pfizer deposited x-ray coordinates of the catalytic domain of a mutant Plk1(complexed with BI2536) in the protein data bank earlier this year. Additional structure factors have been deposited by Sunesis scientists, although the coordinates have not yet been released.

Related posts:

1. Targeting ‘Normal’ Proteins to Kill Cancer Cells For the most part, cancer therapy has been aimed at exploiting pathways that are present in cancer cells and not...
2. Targeting ‘Normal’ Cells to Treat Cancer Most cancer treatments directly target the cancerous cells but tumours are a heterogeneous mix of transformed cells and ‘normal’...
3. Mitochondrial Dysfunction and Polo-Like Kinases The observation that cancer cells have a high rate of glycolysis, even in the presence of oxygen, was first made...
4. Antibody Recruiting Molecules Target HIV, Cancer Both HIV and cancer cells have found ways to evade the body’s immune system but researchers at Yale University...
5. Phase III Study for Oxidative Stress Inducer, Elesclomol Synta Pharmaceuticals has recently announced enrolment of 630 patients for a pivotal Phase III trial of elesclomol (STA-4783) in patients...

Related posts brought to you by Yet Another Related Posts Plugin.

 Email This Post

This entry was posted on Tuesday, July 29th, 2008 at 10:29 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.